#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small cell lung cancer recurrent Dilated cardiomyopathy Neoplasm B-cell lymphoma Alpha-1 antitrypsin deficiency Ventricular fibrillation Kaposi's sarcoma Staphylococcal infection Medulloblastoma Henoch-Schonlein purpura Hairy cell leukaemia recurrent Endometrial cancer recurrent Anal squamous cell carcinoma NTRK gene fusion overexpression Congenital nephrogenic diabetes insipidus More trials…

    Learn about Rare Diseases

    Ornithine transcarbamoylase deficiency – Trials in Disease Marginal zone lymphoma refractory Activated PI3 kinase delta syndrome – Trials in Disease Lymphangiosarcoma – Diagnostics Pulmonary fibrosis – Trials in Disease Chordoma – Treatment VEXAS syndrome – Diagnostics KBG syndrome – Life with Disease Haemophilia – Treatment Glomerulonephritis rapidly progressive – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    4-Hydroxy-N-Desmethyltamoxifen Bhv-7000 Vismodegib GSKVX000000030810 Jk08 MB-001 SIPAVIBART Siltuximab Ribonucleic Acid K30 Epirubicin Hydrochloride Dacarbazine Citrate Vidutolimod VERTEPORFIN Burfiralimab Mb-Cart20.1 ANGIOTENSIN II Human Coagulation Factor Vii Sodium Iodide (123 I) BW-20805 Anhydrous Glucose Bp More therapies…

    Learn about Your Condition

    Large cell lung cancer Procedural anxiety Prostate cancer metastatic Infertility female Oesophageal achalasia Limb reduction defect Chronic hepatitis B Uterine cancer Tympanic membrane hyperaemia Cholecystitis acute Thrombocytosis Polyneuropathy Oral neoplasm Sickle cell anaemia Abdominal infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Petosemtamab
    • Pembrolizumab
    Austria Belgium Croatia Czechia France Germany +8

  • Study of ICT01 and Pembrolizumab for Patients with Advanced-Stage, Relapsed/Refractory Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Haematological malignancy
    • Neoplasm malignant
    Investigated Drugs:
    • Ict01
    • Pembrolizumab
    Belgium France Germany Spain

  • Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Multiple system atrophy
    • Parkinson’s disease
    Investigated Drugs:
    • Exidavnemab
    Poland Spain

  • Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency
    Investigated Drugs:
    • Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
    France Hungary Italy Spain Sweden

  • Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Loperamide
    • Zanidatamab
    • Trastuzumab
    Belgium Estonia France Germany Greece Ireland +6

  • Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    • Follicular lymphoma
    Investigated Drugs:
    • Vincristine
    • Cyclophosphamide
    • Doxorubicin
    Belgium France
Previous Page
1 … 1,686 1,687 1,688 1,689 1,690 … 1,695
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!